AU2015350103A1 - Engineered gamma delta T-cells - Google Patents

Engineered gamma delta T-cells Download PDF

Info

Publication number
AU2015350103A1
AU2015350103A1 AU2015350103A AU2015350103A AU2015350103A1 AU 2015350103 A1 AU2015350103 A1 AU 2015350103A1 AU 2015350103 A AU2015350103 A AU 2015350103A AU 2015350103 A AU2015350103 A AU 2015350103A AU 2015350103 A1 AU2015350103 A1 AU 2015350103A1
Authority
AU
Australia
Prior art keywords
cell
engineered
antigen
cells
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015350103A
Other languages
English (en)
Inventor
Orit Foord
Aya Jakobovits
Andy An-Deh Lin
Marianne Theresa Santaguida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Adicet Bio Inc
Original Assignee
Adicet Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adicet Bio Inc filed Critical Adicet Bio Inc
Publication of AU2015350103A1 publication Critical patent/AU2015350103A1/en
Priority to AU2021221785A priority Critical patent/AU2021221785B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/33—Antibodies; T-cell engagers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4212—CD22, BL-CAM, siglec-2 or sialic acid binding Ig-related lectin 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A61K40/4255—Mesothelin [MSLN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4264—Cancer antigens from embryonic or fetal origin
    • A61K40/4266—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4274—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/45—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2015350103A 2014-11-17 2015-11-17 Engineered gamma delta T-cells Abandoned AU2015350103A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021221785A AU2021221785B2 (en) 2014-11-17 2021-08-25 Engineered gamma delta T-cells

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080500P 2014-11-17 2014-11-17
US62/080,500 2014-11-17
PCT/US2015/061189 WO2016081518A2 (en) 2014-11-17 2015-11-17 Engineered gamma delta t-cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021221785A Division AU2021221785B2 (en) 2014-11-17 2021-08-25 Engineered gamma delta T-cells

Publications (1)

Publication Number Publication Date
AU2015350103A1 true AU2015350103A1 (en) 2017-06-29

Family

ID=56014675

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2015350103A Abandoned AU2015350103A1 (en) 2014-11-17 2015-11-17 Engineered gamma delta T-cells
AU2021221785A Active AU2021221785B2 (en) 2014-11-17 2021-08-25 Engineered gamma delta T-cells

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021221785A Active AU2021221785B2 (en) 2014-11-17 2021-08-25 Engineered gamma delta T-cells

Country Status (14)

Country Link
US (2) US11135245B2 (cg-RX-API-DMAC7.html)
EP (2) EP4545639A3 (cg-RX-API-DMAC7.html)
JP (2) JP7146397B2 (cg-RX-API-DMAC7.html)
KR (1) KR102660362B1 (cg-RX-API-DMAC7.html)
CN (2) CN117143814A (cg-RX-API-DMAC7.html)
AU (2) AU2015350103A1 (cg-RX-API-DMAC7.html)
CA (1) CA2966634C (cg-RX-API-DMAC7.html)
DK (1) DK3220926T3 (cg-RX-API-DMAC7.html)
ES (1) ES3023783T3 (cg-RX-API-DMAC7.html)
IL (2) IL252131B2 (cg-RX-API-DMAC7.html)
MX (1) MX2017006408A (cg-RX-API-DMAC7.html)
RU (1) RU2756247C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016081518A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703505B (cg-RX-API-DMAC7.html)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT1814580T (lt) 2004-11-24 2016-12-12 Fred Hutchinson Cancer Research Center Il 21 naudojimo pritaikomajai imunoterapijai ir naviko antigenų identifikavimo metodai
GB201506423D0 (en) 2015-04-15 2015-05-27 Tc Biopharm Ltd Gamma delta T cells and uses thereof
AU2015350103A1 (en) 2014-11-17 2017-06-29 Adicet Bio, Inc. Engineered gamma delta T-cells
WO2016122320A1 (en) 2015-01-27 2016-08-04 Stichting Vu-Vumc Single domain antibodies targeting cd1d
GB201507368D0 (en) 2015-04-30 2015-06-17 Ucl Business Plc Cell
ES2908840T3 (es) 2015-06-09 2022-05-04 Lymphact Lymphocyte Activation Tech S A Procedimiento para la producción de células T TCR gamma delta+
EP3344760B1 (en) 2015-09-03 2022-01-12 The UAB Research Foundation Genetically-engineered drug resistant t cells and methods of using the same
EP3454870A4 (en) * 2016-05-12 2020-03-04 Adicet Bio Inc. METHOD FOR SELECTIVE EXPANSION OF GAMMA DELTA T CELL POPULATIONS AND COMPOSITIONS THEREOF
US10426796B2 (en) * 2016-06-13 2019-10-01 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
US10456423B2 (en) 2016-06-13 2019-10-29 SMART SURGICAL, Inc. Compositions for biological systems and methods for preparing and using the same
CA3032429A1 (en) 2016-08-03 2018-02-08 Washington University Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
KR102032354B1 (ko) 2016-11-11 2019-10-16 가톨릭대학교 산학협력단 신규한 배양보조세포 및 이를 이용한 감마 델타 ｔ 세포의 증식 방법
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
CA3047999A1 (en) * 2016-12-21 2018-06-28 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
EP3580331B1 (en) * 2017-02-08 2022-06-01 Agency For Science, Technology And Research Gamma delta t cells and a method of augmenting the tumoricidal activity of the same
JP2020511464A (ja) 2017-03-15 2020-04-16 オルカ バイオシステムズ インコーポレイテッド 造血幹細胞移植用の組成物および方法
GB201707048D0 (en) * 2017-05-03 2017-06-14 King S College London Expansion of gamma delta cells, compositions, and methods of use thereof
US12384830B2 (en) * 2017-06-02 2025-08-12 Regents Of The University Of Minnesota Compositions and methods for improving immunotherapy
WO2018236986A1 (en) * 2017-06-20 2018-12-27 The Trustees Of Columbia University In The City Of New York Engineered t-cell receptors and methods of their use
WO2019005897A1 (en) 2017-06-28 2019-01-03 Regeneron Pharmaceuticals, Inc. HUMAN ANTI-PAPILLOMAVIRUS ANTIGEN BINDING PROTEINS AND METHODS OF USE THEREOF
EP3681996B1 (en) * 2017-09-15 2024-08-07 King's College London Compositions and methods for enhancing gamma delta t cells in the gut
TWI687227B (zh) * 2017-10-03 2020-03-11 生倍科技股份有限公司 用於t細胞免疫療法之組合及其用途
CN109777778B (zh) * 2017-11-14 2023-07-18 中国科学院广州生物医药与健康研究院 一种基因改造的γδT细胞
AU2018370120C1 (en) * 2017-11-15 2024-05-30 Adicet Therapeutics, Inc. Methods for selective expansion of d3 yd T-cell populations and compositions thereof
DE102017127984B4 (de) 2017-11-27 2019-12-05 Immatics US, Inc. Verfahren für die Vermehrung und Aktivierung von γδ-T-Zellen
CN108129566B (zh) * 2017-12-31 2021-05-11 中国科学院武汉病毒研究所 靶向间皮素的c-型单域抗体及其制备方法与应用
US12215154B2 (en) 2018-01-19 2025-02-04 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting γδ T cells with chimeric antigen receptors
US12077598B2 (en) 2018-03-16 2024-09-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. Chimeric antigen receptors with mutated CD28 phosphorylation sites
GB201804701D0 (en) 2018-03-23 2018-05-09 Gammadelta Therapeutics Ltd Lymphocytes expressing heterologous targeting constructs
CN112218945A (zh) * 2018-05-08 2021-01-12 国立大学法人大阪大学 纯合细胞的制作方法
CN110577932A (zh) * 2018-06-07 2019-12-17 亘喜生物科技（上海）有限公司 一种脐带血来源的嵌合抗原受体t细胞
EP3823993A1 (en) * 2018-07-18 2021-05-26 Amgen Inc. Chimeric receptors to steap1 and methods of use thereof
EP4650007A2 (en) 2018-08-01 2025-11-19 Imcheck Therapeutics Anti-btn3a antibodies and their use in treating cancer or infectious disorders
CN108949685B (zh) * 2018-08-02 2022-03-29 吉林大学第一医院 一种体外诱导扩增高杀伤活性γδT细胞的方法
WO2020033464A1 (en) 2018-08-07 2020-02-13 H. Lee Moffitt Cancer Center And Research Institute Inc. Car t-cells for the treatment of bone metastatic cancer
US20210177903A1 (en) * 2018-08-07 2021-06-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Car t-cells for the treatment of bone metastatic cancer
CN112105724A (zh) * 2018-08-09 2020-12-18 深圳华大生命科学研究院 无内源hla基因背景的抗原递呈细胞系的构建方法、抗原递呈细胞系及其用途
CN112567025B (zh) * 2018-08-10 2025-01-17 国立大学法人京都大学 Cd3阳性细胞的制造方法
CN113307872B (zh) * 2018-08-11 2022-12-06 广东天科雅生物医药科技有限公司 一种工程化核酸、t细胞及其应用和产生方法
CN109161533B (zh) * 2018-08-28 2020-07-24 深圳市菲鹏生物制药股份有限公司 无血清培养组合物及其应用
CN113260629A (zh) 2018-09-19 2021-08-13 拉法医疗有限公司 用于治疗恶性血液病的新双特异性抗体
BR112021006254A2 (pt) * 2018-10-01 2021-07-27 Adicet Bio, Inc. composições e métodos relativos a células t¿d engenheiradas e não engenheiradas para tratamento de tumores sólidos
AU2019354391A1 (en) * 2018-10-01 2021-05-06 Adicet Therapeutics, Inc. Compositions and methods regarding engineered and non- engineered γδ-Τ cells for treatment of hematological tumors
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
JP7569313B2 (ja) 2018-10-23 2024-10-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｎｙ－ｅｓｏ－１ ｔ細胞受容体およびそれらの使用の方法
GB201818243D0 (en) 2018-11-08 2018-12-26 Gammadelta Therapeutics Ltd Methods for isolating and expanding cells
CA3126896A1 (en) 2018-12-03 2020-06-11 Adicet Bio Inc. Methods for selective in vivo expansion of .gamma. .delta. t-cell populations and compositions thereof
CN111544585B (zh) * 2019-02-11 2024-12-27 北京卡替医疗技术有限公司 一种可助推免疫细胞在体内扩增的佐剂
JP6884450B2 (ja) * 2019-02-14 2021-06-09 学校法人獨協学園獨協医科大学 Ｔ細胞ワクチン
AU2020226401A1 (en) * 2019-02-18 2021-10-14 Memorial Sloan-Kettering Cancer Center Combinations of multiple chimeric antigen receptors for immunotherapy
EP3927353A4 (en) * 2019-02-24 2022-11-23 Gamida-Cell Ltd. METHOD OF ECOTAXY AND RETENTION OF GAMMADELTA T LYMPHOCYTES, OPTIONALLY WITH NATURAL KILLER CELLS, ALLOWING THE GENERATION OF CELLULAR COMPOSITIONS FOR USE IN THERAPY
AU2020237633B2 (en) * 2019-03-08 2025-08-28 Klinikum Der Universität München CCR8 expressing lymphocytes for targeted tumor therapy
CN109758590B (zh) * 2019-03-28 2022-02-11 广东工业大学 一种用于筛选人前列腺癌肿瘤抗原表位肽的方法
PH12021552476A1 (en) * 2019-03-30 2022-07-18 Biontech Us Inc Compositions and methods for preparing t cell compositions and uses thereof
US12404331B2 (en) 2019-04-19 2025-09-02 Tcrcure Biopharma Corp. Anti-PD-1 antibodies and uses thereof
EP3959236A4 (en) * 2019-04-26 2023-01-25 The University of North Carolina at Chapel Hill CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND THEIR USE IN CAR-T CELLS
US11667712B2 (en) * 2019-05-08 2023-06-06 Janssen Biotech, Inc. Materials and methods for modulating t cell mediated immunity
EP3999187A4 (en) * 2019-07-17 2023-07-19 Case Western Reserve University LONG-LASTING T-CELLS FOR THE TREATMENT OF HIV INFECTION
WO2021016652A1 (en) * 2019-07-29 2021-02-04 The University Of Melbourne METHODS AND COMPOSITIONS FOR MONITORING, TREATING AND PREVENTING CMV INFECTION OR GRAFT REJECTION USING γδ T-CELLS
CA3145523A1 (en) * 2019-08-16 2021-02-25 GammaDelta Therapeutics Limited Therapeutic uses of anti-tcr delta variable 1 antibodies
US20220387489A1 (en) * 2019-10-17 2022-12-08 The University Of Hong Kong Methods to prepare v-t cells derived exosomes for treatment of epstein-barr virus-associated cancers
DK4051710T3 (da) 2019-10-31 2025-12-15 Incyte Corp Antitumor-kombinationsterapi bestående af anti-cd19-antistof og gamma-delta-t-celler
IL293459A (en) * 2019-12-03 2022-07-01 Adicet Bio Inc Methods for expanding γδ t-cell populations with multivalent agents and compositions thereof
IL294988A (en) 2020-01-24 2022-09-01 Regeneron Pharma Antigen preferentially expressed in melanoma t-cell receptors (prame) and methods of using them
AU2021232141A1 (en) * 2020-03-03 2022-09-22 Janssen Biotech, Inc. ꝩδ T cells and uses thereof
CA3158133A1 (en) 2020-04-28 2021-11-04 Lyell Immunopharma, Inc. Methods for culturing cells
WO2021259237A1 (en) * 2020-06-22 2021-12-30 Nanjing Legend Biotech Co., Ltd. GENETIC ENGINEERING OF γδ T CELLS FOR IMMUNOTHERAPY
CN116323667A (zh) 2020-07-08 2023-06-23 拉法医疗股份有限公司 结合PSMA和γ-δT细胞受体的抗体
CN116333984A (zh) * 2020-07-14 2023-06-27 广州泛恩生物科技有限公司 基于galnt2阳性t细胞的用于杀伤肿瘤的tcr-t细胞及其制备方法和应用
WO2022170344A1 (en) * 2021-02-08 2022-08-11 Alexander Marson Regulation of butvrophilin subfamily 3 member a1 (btn3a1, cd277)
GB202105113D0 (en) * 2021-04-09 2021-05-26 Gammadelta Therapeutics Ltd Novel method
EP4419118A4 (en) * 2021-10-20 2025-04-30 University of Pittsburgh - Of the Commonwealth System of Higher Education Methods and materials for expanding tumor infiltrating gamma-delta t cells
WO2023092119A2 (en) 2021-11-22 2023-05-25 Ludwig Institute For Cancer Research Ltd Methods for predicting responsiveness to a cancer therapy
CN118524843A (zh) * 2021-12-05 2024-08-20 阿迪塞特治疗公司 B细胞恶性肿瘤的治疗
KR20230105166A (ko) 2022-01-03 2023-07-11 주식회사 이뮤노맥스 감마-델타 t 세포의 증식 배양 방법
CN114149978B (zh) * 2022-02-09 2022-04-26 深圳博雅感知药业有限公司 制备car-t细胞的方法
IL314940A (en) 2022-02-16 2024-10-01 Priothera Sas Methods of treatment with car cells in combination with s1p receptor modulators
GB202204926D0 (en) 2022-04-04 2022-05-18 Gammadelta Therapeutics Ltd Method for expanding gammadelta T cells
WO2023242434A1 (en) * 2022-06-17 2023-12-21 Gadeta B.V. Modified immune cells
CN115624618A (zh) * 2022-09-16 2023-01-20 深圳善乐生物科技有限公司 一种HPV多肽抗原负载γδT细胞在HPV阳性宫颈癌免疫治疗中的应用
IL320128A (en) 2022-10-31 2025-06-01 Regeneron Pharma Methods for treating cancer using a combination of adoptive cell therapy and a targeted immunocytokine
WO2024211478A1 (en) 2023-04-07 2024-10-10 Regeneron Pharmaceuticals, Inc. Methods of treating cancer with a lymphotoxin beta receptor agonist
WO2024243511A1 (en) 2023-05-25 2024-11-28 Regeneron Pharmaceuticals, Inc. T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides
US12221483B1 (en) * 2024-01-30 2025-02-11 China Medical University Hospital Fusion protein and nucleic acid encoding sequence thereof, and uses of the same
WO2025165915A1 (en) * 2024-01-31 2025-08-07 Adicet Therapeutics, Inc. Compositions and methods for enhancing engineered t cell therapies
WO2025229538A1 (en) * 2024-05-01 2025-11-06 Janssen Biotech, Inc. Materials, methods, and systems for cellular expansion of gamma delta t-cells

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260223A (en) 1986-07-03 1993-11-09 President & Fellows Of Harvard College Methods for detection of human gamma, γ T cell receptor
US5185250A (en) * 1986-07-03 1993-02-09 T Cell Sciences, Inc. Human γ, δT cell antigen receptor polypeptides and nucleic acids
JPH07505773A (ja) 1992-04-03 1995-06-29 ヤング　アレキサンダー　ティー 標的化されたウイルスベクターを用いた遺伝子治療
CA2110946A1 (en) 1992-12-09 1994-06-10 Elazar Rabbani Induction of immunocompatibility by nucleic acid
EP1189635A4 (en) 1999-06-17 2003-04-23 Univ Vermont AUTOLOGOUS ADOPTIVE IMMUNOTHERAPY WITH T-CELLS OR B-CELLS B WHICH HAVE BEEN SENSITIZED TO ANTIGENS-SPECIFIC
US6737398B1 (en) 1999-09-30 2004-05-18 National Jewish Medical And Research Center Modulation of γδ T cells to regulate airway hyperresponsiveness
EP1229790A4 (en) 1999-09-30 2004-06-16 Nat Jewish Med & Res Center MODULATION OF -G (G) -G (D) T CELLS FOR REGULATING THE RESPIRATORY HYPERSENSITIVITY
CN100575485C (zh) 2002-01-23 2009-12-30 犹他大学研究基金会 使用锌指核酸酶的定向染色体诱变
CN1306027C (zh) 2002-12-12 2007-03-21 中国医学科学院基础医学研究所 一种体外扩增γδT淋巴细胞的方法
WO2004092741A2 (en) 2003-04-14 2004-10-28 Montana State University Mapping discontinuous antibody or aptamer epitopes for protein structure determination and other applications
US7985739B2 (en) 2003-06-04 2011-07-26 The Board Of Trustees Of The Leland Stanford Junior University Enhanced sleeping beauty transposon system and methods for using the same
SG188175A1 (en) * 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
US7340913B2 (en) 2004-08-05 2008-03-11 Manitowoc Foodservice Companies, Inc. Ice machine and ice-making assembly including a water distributor
US20080026986A1 (en) * 2006-06-05 2008-01-31 Rong-Fu Wang Reversal of the suppressive function of specific t cells via toll-like receptor 8 signaling
MY161894A (en) * 2006-09-08 2017-05-15 Abbvie Bahamas Ltd Interleukin-13 binding proteins
CA2735193A1 (en) 2008-08-26 2010-03-11 Macrogenics, Inc. T-cell receptor antibodies and methods of use thereof
EA031322B1 (ru) 2010-01-22 2018-12-28 Дау Агросайенсиз Ллс Клетка или клеточная линия для экспрессии экзогенных нуклеотидных последовательностей и применение клетки или клеточной линии
CA2805442C (en) 2010-07-21 2020-05-12 Sangamo Biosciences, Inc. Methods and compositions for modification of an hla locus
EP2694553B1 (en) 2011-04-01 2017-10-11 Memorial Sloan-Kettering Cancer Center T cell receptor-like antibodies specific for a wt1 peptide presented by hla-a2
PT2710123T (pt) 2011-05-19 2017-10-13 Inst De Medicina Molecular Linha celular de linfócitos compreendendo células t gama-delta, método de composição e produção resultante dos mesmos
WO2013074916A1 (en) * 2011-11-18 2013-05-23 Board Of Regents, The University Of Texas System Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla
KR101764096B1 (ko) 2011-11-28 2017-08-02 메르크 파텐트 게엠베하 항-ｐｄ-ｌ1 항체 및 그의 용도
CN103130894B (zh) * 2011-11-30 2017-04-12 中国医学科学院基础医学研究所 抗人γδTCR单克隆抗体的重组单链抗体G5‑4ScFv及其编码基因与应用
EP2684600A1 (en) 2012-07-10 2014-01-15 Laboratoires Meiners Sarl Core-shell capsules and methods for encapsulation of reactive ingredients by diffusional exchange through spherical capsule membranes
JP2016501013A (ja) 2012-11-08 2016-01-18 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル γδＴ細胞の無ＩＬ−２増殖を誘導するための方法
CN102994448A (zh) * 2012-12-13 2013-03-27 上海柯莱逊生物技术有限公司 一种体外扩增γδT细胞的方法
WO2014134412A1 (en) 2013-03-01 2014-09-04 Regents Of The University Of Minnesota Talen-based gene correction
KR20160068960A (ko) 2013-10-25 2016-06-15 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 면역요법을 위한 다클론성 감마 델타 t 세포
JP6617138B2 (ja) * 2014-04-10 2019-12-11 ラヴァ・セラピューティクス・ベー・フェー ヒトＶγ９Ｖδ２ Ｔ細胞受容体と結合する免疫グロブリン
AU2015350103A1 (en) 2014-11-17 2017-06-29 Adicet Bio, Inc. Engineered gamma delta T-cells
WO2016198480A1 (en) * 2015-06-09 2016-12-15 Lymphact - Lymphocyte Activation Technologies, S.A. Methods for the production of tcr gamma delta+ t cells
MA42895A (fr) 2015-07-15 2018-05-23 Juno Therapeutics Inc Cellules modifiées pour thérapie cellulaire adoptive
US10519236B2 (en) 2018-01-23 2019-12-31 New York University Antibodies specific to delta 1 chain of T cell receptor

Also Published As

Publication number Publication date
IL297773A (en) 2022-12-01
KR102660362B1 (ko) 2024-04-23
EP4545639A2 (en) 2025-04-30
US20220160765A1 (en) 2022-05-26
IL252131B (en) 2022-12-01
KR20170101206A (ko) 2017-09-05
IL297773B2 (en) 2024-07-01
ES3023783T3 (en) 2025-06-03
US12371663B2 (en) 2025-07-29
JP2017535292A (ja) 2017-11-30
EP4545639A3 (en) 2025-08-06
MX2017006408A (es) 2018-03-23
EP3220926A2 (en) 2017-09-27
AU2021221785B2 (en) 2025-02-13
CN117143814A (zh) 2023-12-01
RU2017121115A3 (cg-RX-API-DMAC7.html) 2019-07-17
US20160175358A1 (en) 2016-06-23
EP3220926B1 (en) 2024-12-25
US11135245B2 (en) 2021-10-05
IL252131A0 (en) 2017-07-31
DK3220926T3 (da) 2025-03-24
RU2756247C2 (ru) 2021-09-28
WO2016081518A2 (en) 2016-05-26
AU2021221785A1 (en) 2021-09-23
RU2017121115A (ru) 2018-12-19
EP3220926A4 (en) 2018-08-08
JP2021072787A (ja) 2021-05-13
IL297773B1 (en) 2024-03-01
IL252131B2 (en) 2023-04-01
JP7146397B2 (ja) 2022-10-04
CA2966634C (en) 2024-04-23
JP7317793B2 (ja) 2023-07-31
CN107249605A (zh) 2017-10-13
WO2016081518A3 (en) 2016-08-18
CA2966634A1 (en) 2016-05-26
ZA201703505B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
AU2021221785B2 (en) Engineered gamma delta T-cells
US12364714B2 (en) Methods for selective expansion of gamma delta t-cell populations and compositions thereof
US20230009275A1 (en) Methods for expanding gamma delta t-cell populations with multivalent agents and compositions thereof
EP3710472A1 (en) Methods for selective expansion of delta 3 gamma delta t-cell populations and compositions thereof
HK1242585A1 (en) Engineered gamma delta t-cells
HK1242585B (en) Engineered gamma delta t-cells

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted